Skip to main content
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 2.88
Day High 2.96
Open:2.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Cardiol Therapeutics Inc produces pharmaceutical cannabidiol and develops innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Their lead product, CardiolRx, is pharmaceutically produced, manufactured under cGMP, THC free, and designed to be one of the safest and most consistent cannabidiol formulations. An international clinical study of CardiolRx is planned in acute myocarditis, a condition caused by inflammation in heart tissue and the most common cause of sudden cardiac death in young people. The company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol directly to sites of inflammation in the heart that are associated with heart failure.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
- Newsfile Corp - Tue Oct 20, 6:28AM CDT
Newsfile Corp - CMTX
Tue Oct 20, 6:28AM CDT
() () ("" or the ""), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce the commercial introduction of Cortalex, a THC-free* extra-strength (100 mg/mL concentration) oral cannabidiol (CBD) formulation. Cortalex is now available across Canada exclusively at online portal, a subsidiary of , and is the first pharmaceutically produced CBD specifically formulated for the large number of patients who should not be exposed to tetrahydrocannabinol (THC).
FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com
- Newsfile Corp - Wed Sep 30, 8:00AM CDT
Newsfile Corp - CMTX
Wed Sep 30, 8:00AM CDT
Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Administration (FDA) an Investigational New Drug application by (TSX: CRDL) (OTCQX: CRTPF) that opens the door for Cardiol to conduct its Phase II/III trial. The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
IIROC Trade Resumption - CRDL
- PR Newswire - Fri Sep 25, 6:55AM CDT
PR Newswire - PRNW
Fri Sep 25, 6:55AM CDT
TORONTO , Sept. 25, 2020 /CNW/ - Trading resumes in:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.81 +3.56% increase
on 10/02/20
Period Open:2.98
Price movement based on the high, low and last over the given period.
3.75 -22.40% decrease
on 10/19/20
-0.07 (-2.35%) decrease
since 09/25/20
3-Month 1.98 +46.97% increase
on 08/12/20
Period Open:2.50
Price movement based on the high, low and last over the given period.
3.75 -22.40% decrease
on 10/19/20
+0.41 (+16.40%) increase
since 07/27/20
52-Week 1.87 +55.61% increase
on 03/18/20
Period Open:3.60
Price movement based on the high, low and last over the given period.
5.00 -41.80% decrease
on 01/06/20
-0.69 (-19.17%) decrease
since 10/25/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies